Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last C$0.02 CAD
Change Today 0.00 / 0.00%
Volume 102.6K
MOM On Other Exchanges
As of 3:51 PM 02/12/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

6-1250 Waverley Street

Winnipeg, MB R3T 6C6


Phone: 204-453-1408

Fax: 204-453-1546

Miraculins, Inc., a development stage company, engages in the discovery and development of therapeutics and diagnostics for human disorders. Prostate Cancer Program The company has an agreement with CMX Research, Inc., a site management organization (SMO), which is conducting pharmaceutical, biotech and medical device research at 32 locations across Canada. In 2007, the company filed a pre-IDE (Investigational Device Exemption) submission with the U.S. Food and Drug Administration, in preparation for its planned clinical study for its P2V prostate cancer diagnostic test. Colorectal Cancer Program The company owns intellectual property related to various biomarkers indicated for colorectal cancer and is executing a research program to validate the ability of these markers to diagnose this disease. The company has into a collaboration agreement with the Fox Chase Cancer Center for the validation phase of its research work. Pancreatic, Gastric, and Breast Cancer Programs The company has intellectual property related to pancreatic, gastric, and breast cancers that require research. It focuses on its prostate and colorectal cancer programs, and evaluates the next steps for these cancer programs. Other Opportunities In addition to research programs, the company has various complimentary patents cancer areas and is in the process of planning specific research programs that would verify the utility of this intellectual property. Significant Events On January 07, 2010, the company has entered into a partnership with Inverness Medical Innovations Inc. to advance and commercialize Miraculins' preeclampsia technology. History Miraculins, Inc. was incorporated in 1998.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOM:CN C$0.02 CAD 0.00

MOM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Health Discovery Corp $0.03 USD -0.0002
Imperial Innovations Group PLC 409.88 GBp +12.38
MDxHealth €3.35 EUR +0.09
Myriad Genetics Inc $34.21 USD +0.09
Vermillion Inc $1.25 USD +0.0799
View Industry Companies

Industry Analysis


Industry Average

Valuation MOM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MIRACULINS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at